



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

09/874,141

06/06/2001

Darrell Anderson

037003-0280632

6256

909

7590

06/25/2007

PILLSBURY WINTHROP SHAW PITTMAN, LLP

P.O. BOX 10500

MCLEAN, VA 22102

EXAMINER

GAMBEL, PHILLIP

ART UNIT

PAPER NUMBER

1644

MAIL DATE

DELIVERY MODE

06/25/2007

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

## Office Action Summary

Application No.

09/874,141

Applicant(s)

ANDERSON ET AL.

Examiner

Phillip Gambel

Art Unit

1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 11 June 2007.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 2,3,5,16-21,30 and 32-42 is/are pending in the application.
- 4a) Of the above claim(s) 39-42 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 2,3,5,16-21,30 and 32-38 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                       | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

Art Unit: 1644

### DETAILED ACTION

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office Action as been withdrawn pursuant to 37 CFR 1.114.

Applicant's submission filed on 06/11/2007 has been entered.

Applicant's amendment, filed 06/11/2007, has been entered.

Claims 23-27 have been canceled.

Claims 1, 4, 6-15, 22, 28-29 and 31 have been canceled previously.

Claims 2, 30 and 33 have been amended.

Claims 39-42 have been added

Claims 2, 3, 5, 16-21, 30, and 32-42 are pending.

Newly submitted claims 39-42 are directed to an invention that is independent or distinct from the invention originally claimed for the following reasons:

Newly submitted claims 39-42 are drawn to in vitro methods of assaying for non-agonistic or antagonistic anti-gp39 antibodies, which differs in ingredients, process steps and endpoints with the methods of treating autoimmune diseases previously acted upon. Further, it is noted that the newly added claims 39-42 are in vitro screening assays, while the original invention has been drawn to in vivo therapeutic methods.

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits.

Accordingly, claims 39-42 are withdrawn from consideration as being directed to a non-elected invention. See 37 C.F.R. 1.142(b) and M.P.E.P. 821.03.

Applicant's election with traverse of multiple sclerosis (Group II-C) as the disease species has been acknowledged.

Claims 2, 3, 5, 16-21, 23-27, 30 and 32-38 as they read on treating multiple sclerosis with anti-gp39 antibodies are under consideration as the elected invention.

Art Unit: 1644

2. The text of those sections of Title 35 USC not included in this Action can be found in a prior Office Action.

This Action will be in response to applicant's amendment, filed 11/6/06.

The rejections of record can be found in the previous Office Actions, mailed 06/06/2006 and 01/26/2007.

Applicant's arguments and the examiner's rebuttal appear to be essentially the same of record.

3. Claims 2, 3, 5, 16-21 and 23-27, 30 and 32-38 stand rejected under 35 U.S.C. § 103(a) as being unpatentable over Black et al. (U.S. Patent No. 6,001,358) in view of the art known methods to screen for inhibitors of cytokines and proliferation in view of Schrader et al. (U.S. Patent No. 5,627,052), Burkly et al. (US2002/0028202 A1), Wilson et al. (U.S. Patent No. 6,372,208 B1), Van den Eertwegh et al. (J. Exp. Med. 178: 1555-1565, 1993) and Roy et al. (J. Immunol. 151: 2497-2510, 1993) essentially for the reasons of record.

Applicant's arguments, filed 06/11/2007, have been fully considered but are not found convincing essentially for the reasons of record.

Applicant's arguments and the examiner's rebuttal are essentially the same of record.

A. Rebuttal: The cited references failed to teach or suggest all elements of the claimed invention.

Again, applicant submits that the neither the combination of references nor the general knowledge of the ordinary artisan would have provided the suggestion or motivation to perform the claimed methods with an expectation of success.

Art Unit: 1644

In contrast to applicant's assertions, that Black et al. (U.S. Patent No. 6,001,358), the primary reference, does not teach or suggest assaying to identify soluble anti-human gp39 antibodies that inhibit the interaction of human gp39 with CD40 and are non-agonistic of an activation response by purified human CD4<sup>+</sup> T-cells that have been cultured in vitro with immobilized anti-CD3 antibodies, which activation response is selected from the group consisting of T-cell proliferation and that the cited examples of Black et al., like the document as a whole, are concerned with the effects on B cells of signals delivered by gp39<sup>+</sup> T cells to the B cells via CD40;

the combined teachings clearly taught the importance of CD40 ligand expressing T cells and subsequent effector functions in the context of IL-2, IL-4 and  $\gamma$ -interferon, provided clear teachings of the known assays to test inhibitory antibodies, antibodies that inhibit T cell activation and proliferation, including antibodies that inhibit CD40 ligand:CD40 interactions, at the time the invention was made.

While applicant acknowledges the prior art teachings of blocking signals mediated via CD40L:CD40 interactions,

again, applicant appears to limit the prior art to the individual teachings presented in each prior art reference, such as the prior art concerns with B cells and not with the effects of such blocking on the very target of the anti-gp39 antibodies (i.e., anti-CD40L antibodies), namely the gp39-expressing CD4<sup>+</sup> T cells and the nature of the signals by which said gp39-expressing CD4<sup>+</sup> T cells were known to operate (e.g., cytokines).

While applicant acknowledges that the prior art provided for testing the role of anti-gp39 antibodies (e.g. anti-CD40L antibodies) on antigen-presenting cells such as CD40-expressing B cells and dendritic cells;

again applicant continues to assert that no such motivation and expectation of success is provided in the prior art about testing the very target of the of the anti-gp39 antibodies (i.e., anti-CD40L antibodies), namely the gp39-expressing CD4<sup>+</sup> T cells and the nature of the signals by which said gp39-expressing CD4<sup>+</sup> T cells were known to operate (e.g., cytokines) and as taught and evidenced by the prior art of record.

As indicated previously, once a prima facie case of obviousness has been made the burden of going further is shifted to applicant. In re Keller, 208 USPQ 871, 882 (CCPA 1981).

This applicant has not done, but rather argues the references individually and not their combination. One cannot show non-obviousness by attacking references individually where the rejections are based on a combination of references. In re Young, 150 USPQ 725 (CCPA 1968). See MPEP 2145.

Art Unit: 1644

Obviousness can be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art. See In re Fine 5 USPQ2d 1596 (Fed. Cir. 1988) and In re Jones 21 USPQ2d 1941 (Fed. Cir. 1992).

In contrast to applicant's assertions that the combination of cited references neither teaches nor suggests the method of the claimed invention comprising assaying in vitro to identify soluble anti-human gp39 antibodies of the previous step that are non-agonistic of an activation response by purified human CD4+ T-cells that have been cultured in vitro with immobilized anti-CD3 antibodies, wherein the activation response is selected from the group consisting of T-cell proliferation, the production of IL-2, the production of IL-4, and the production of IFN- $\gamma$ ;

the teachings of the secondary references, including the previously added Van den Eertwegh et al and Roy et al. references, which clearly taught the importance of CD40 ligand expressing T cells and subsequent effector functions in the context of IL-2, IL-4 and interferon- $\gamma$ , provided clear teachings of the known assays to test inhibitory antibodies, antibodies that inhibit T cell activation and proliferation, including antibodies that inhibit CD40 ligand:CD40 interactions.

As noted previously, Van den Eertwegh et al. (J. Exp. Med. 178: 1555-1565, 1993) and Roy et al. (J. Immunol. 151: 2497-2510, 1993) have been provided to make the record clear the CD40 ligand expressing cells involved in T – B cell interactions were associated and analyzed in the context of IL-2, IL-4 and interferon  $\gamma$  at the time the invention was made.

Also as pointed out previously, Van den Eertwegh et al. teach evaluating or analyzing cytokine production associated with IL-2, IL-4 and interferon  $\gamma$  in the context of CD40 ligand- / gp39-expressing T cells in the context of T – B cell interactions in vitro and in vivo and that CD40L gp39 T cell and cytokine producing cell are simultaneously upregulated after immunization (e.g. see Discussion, including the last paragraph on page 1563) (see entire document, including Summary).

In addition, Roy et al. teach the regulation of gp39 / CD40 ligand on normal and cloned human CD4<sup>+</sup> T cells and the importance of the expression of CD40 ligand on activated T cells in determining effector function (see entire document, including the Discussion). Here, the studies were conducted with purified CD4<sup>+</sup> T cells and analysis of IL-2, IL-4 and interferon  $\gamma$  (e.g., see Materials and Methods and Results).

Art Unit: 1644

Therefore, it would have obvious to a person of ordinary skill in the art at the time the invention was made to apply the teachings of Van den Eertwegh et al. and Roy et al. to the teachings of Schrader et al., Burkly et al. and Wilson et al. as well as to those of Black et al. to screen and obtain antagonistic anti-gp39 antibodies with the ability to inhibit cytokines produced by activated T cells, including the inhibition of IL-2, IL-4 and  $\gamma$ -interferon, which were known to be products of the T cells targeted by antagonistic anti-gp39 antibodies, including purified CD4<sup>+</sup> T cells.

For example, Van den Eertwegh et al and Roy et al. provided further evidence that the ordinary artisan understood the importance and role of CD40 ligand expressing T cells and cytokine production in the elaboration of immune response in the context of T-B cell interactions and subsequent effector functions. Note too, that human B cells were known antigen presenting cells at the time the invention was made.

Also, as noted previously, a person of ordinary skill in the art would have been motivated to produce this resultant ability of anti-gp39 antibodies to inhibit cytokine activity by activated T cells in order to test and select for those anti-gp39 antibodies that had the described properties of inhibiting gp39:CD40 interaction and the resultant ability of such antibodies to inhibit T cell mediated activation of immune response in the treatment of various conditions and disorders, including multiple sclerosis.

Both Black et al. and Wilson et al. teach inhibitory anti-CD40 ligand (anti-gp39) antibodies and their effects on T cell mediated activation and functions.

Given the role of various cytokines such as IL-2, IL-4 and  $\gamma$ -interferon, which were known to be products of the T cells targeted by antagonistic anti-gp39 antibodies, play in immune responses, one of ordinary skill in the art would have been motivated to screen and test for the properties of antagonistic anti-CD40 ligand antibodies that inhibited T cell activation and proliferation in the selection of such inhibitory antibodies that can regulate the various manifestations of T cell activation and function.

The strongest rationale for combining reference is a recognition, expressly or implicitly in the prior art or drawn from a convincing line of reasoning based on established scientific principles or legal precedent that some advantage or expected beneficial result would have been produced by their combination In re Sernaker 17 USPQ 1, 5-6 (Fed. Cir. 1983). See MPEP 2144.

"The test of obviousness is not express suggestion of the claimed invention in any or all of the references but rather what the references taken collectively would suggest to those of ordinary skill in the art presumed to be familiar with them." See In re Rosselet, 146 USPQ 183, 186 (CCPA 1965).

Art Unit: 1644

"There is no requirement (under 35 USC 103(a)) that the prior art contain an express suggestion to combine known elements to achieve the claimed invention. Rather, the suggestion to combine may come from the prior art, as filtered through the knowledge of one skilled in the art." Motorola, Inc. v. Interdigital Tech. Corp., 43 USPQ2d 1481, 1489 (Fed. Cir. 1997).

An obviousness determination is not the result of a rigid formula disassociated from the consideration of the facts of a case. Indeed, the common sense of those skilled in the art demonstrates why some combinations would have been obvious where others would not. See KSR Int'l Co. v. Teleflex Inc., 550 U.S. , 2007 U.S. LEXIS 4745, 2007 WL 1237837, at \*12 (2007) ("The combination of familiar elements according to known methods is likely to be obvious when it does no more than yield predictable results.").

Applicant's arguments have not been found persuasive.

B. Rebuttal: The prior art taught away from performing the method of the claimed invention.

A prior art reference may be considered to teach away when "a person of ordinary skill, upon reading the reference, would be discouraged from following the path set out in the reference, or would be led in a direction divergent from the path that was taken by the applicant." In re Gurley, 27 F.3d 551, 553, 31 USPQ2d 1130, 1131 (Fed. Cir. 1994).

General skepticism of those in the art -- not amounting to teaching away -- is also "relevant and persuasive evidence" of nonobviousness. Gillette Co. v. S.C. Johnson & Son, Inc., 16 USPQ2d 1923, 1929 (Fed. Cir. 1990).

In effect, "teaching away" is a more pointed and probative form of skepticism expressed in the prior art. In any case, the presence of either of these indicia gives insight into the question of obviousness.

Here, in contrast to applicant's assertions that the prior art teaching taught away from the claimed methods by teaching that anti-gp39 antibodies inhibit T cell activation responses mediated by multicellular interactions involving APCs such as B cells and dendritic cells,

the combination of references did provide sufficient motivation and expectation of success in screening and obtaining antagonistic anti-gp39 antibodies with the ability to inhibit cytokines produced by activated T cells, including the inhibition of IL-2, IL-4 and  $\gamma$ -interferon, which were known to be products of the T cells targeted by antagonistic anti-gp39 antibodies, including purified CD4<sup>+</sup> T cells at the time the invention was made.

See the rejection of record, reiterated herein as well as the Rebuttal in the Section A above.



Art Unit: 1644

Applicant's arguments have not been found persuasive for the reasons of record.

C. Rebuttal: The cited combination of references also failed to provide a reasonable expectation that the method of the claimed invention could be performed successfully

In contrast to applicant's assertions that it was not known and could not have been predicted at the time the invention was made by one of ordinary skill in the art that soluble anti-human gp39 antibodies are capable of binding to gp39 of purified human CD4<sup>+</sup> T-cells that have been cultured in vitro in the presence of immobilized anti-CD3 antibodies and modulating T cell activation responses such as T cell proliferation and the production of the cytokines IL-2, IL-4, and IFN- $\gamma$  by relying upon references such as Blair et al. and Blotta et al. (of record);

the combination of references did provide sufficient motivation and expectation of success in screening and obtaining antagonistic anti-gp39 antibodies with the ability to inhibit cytokines produced by activated T cells, including the inhibition of IL-2, IL-4 and  $\gamma$ -interferon, which were known to be products of the T cells targeted by antagonistic anti-gp39 antibodies, including purified CD4<sup>+</sup> T cells at the time the invention was made.

See the rejection of record, reiterated herein as well as the *Rebuttal in the Section A above*.

As pointed out previously, while applicant has relied upon the teachings of Blair et al. (J. Exp. Med. 191: 651- 660, 2000) and Blotta et al. (J. Immunol. 156: 3133-3140. 1996) to indicate the agonistic properties of anti-gp39 antibodies on T cells,

it was noted that these references appear to rely upon the cross-linking of anti-gp39 antibodies to achieve such agonistic properties.

In contrast to applicant's assertions that neither the combination of cited references nor the general knowledge of one of ordinary skill in the art at the time the invention was made would have enabled one of ordinary skill in the art to predict that the method of the claimed invention could be performed with a reasonable expectation of success,

the combination of references did provide an enabling prior art based upon well-known and practiced assays by the ordinary artisan at the time the invention was made, as well as providing sufficient motivation and expectation of success in screening and obtaining antagonistic anti-gp39 antibodies with the ability to inhibit cytokines produced by activated T cells, including the inhibition of IL-2, IL-4 and  $\gamma$ -interferon, which were known to be products of the T cells targeted by antagonistic anti-gp39 antibodies, including purified CD4<sup>+</sup> T cells at the time the invention was made.

Art Unit: 1644

Applicant's arguments have not been found persuasive.

Again, the following of record is reiterated for applicant's convenience.

Black et al. teach methods of treating disease condition wherein gp39 inhibition is therapeutically beneficial (columns 13-14 and 31-34), including multiple sclerosis with column 14, line 40 and column 32, line 67) with antibodies that bind gp39 (CD40 ligand), which block signals delivered via CD40 (See Examples 2, 3 columns 22-23; Examples 11-17 on columns 28-38 (see entire document).

In addition, Black et al. teach chimeric, humanized, and primatized antibodies, including the use of different heavy chain constant regions (IgG1, IgG3, IgG4), with conservative amino acid substitutions such as Kabat positions 229 and 236 as well as the 24-31 antibody specificity and its variable regions amino acid sequences encompassed by the claimed methods (see entire document, including Background of the Invention, including columns 6-7; Summary of the Invention; Detailed Description of the Invention, including columns 13-22; Claims). Further, it is noted that Black et al. teach that it was known that gp39<sup>+</sup> T cells produced IL-2, IL-4 and  $\gamma$ -interferon (see column 4, paragraph 1). In addition, Black et al. teach modes of administration and dosages of antagonistic anti-gp39 antibodies encompassed by the claimed methods (see columns 33-38).

Again as noted above, applicant asserts that Black et al. does not describe or suggest a method of obtaining anti-gp39 antibodies that includes steps of assaying for and identifying non-agonistic antibodies with the characteristics of human T cell activation.

As pointed out previously, while applicant has also relied upon the data in Table 5 of Black and the possible distinctions between anti-mouse gp39 antibodies versus anti-human gp39 antibodies to support the unobviousness of the prior art rejection;

it was been pointed out that both Black et al. and Wilson et al. teach inhibitory anti-CD40 ligand (anti-gp39) antibodies and their effects on T cell mediated activation and functions and that Wilson et al. makes no distinction between inhibitory anti-mouse gp39 antibodies versus anti-human gp39 antibodies.

Black et al. differs from the claimed methods by not disclosing the art known use of screening for inhibitors of cytokine activity such as IL-2, IL-4 and  $\gamma$ -interferon as well as cell proliferation per se in selecting antagonistic anti-gp39 antibodies.

Art Unit: 1644

Schrader et al. teach methods of producing antibodies of a desired function to a variety of antigens, including IL-2 and  $\gamma$ -interferon, including the section of antibodies that neutralizes a growth factor or detection of antibodies that neutralize IL-2 (e.g. see columns 8-9, overlapping paragraph) and exemplifies the detection of antibodies that neutralize IL-2 (see Example 1 on columns 21-22) (see entire document, including Summary of the Invention and Detailed Description of the Invention).

Burkly et al. teach known methods of assaying or screening the ability of antagonists such as antibodies to block a response to a particular cytokine (e.g. IL-2) (See GC Chain Blocking Agents and Production of GC Blocking Antibodies on pages 7-8 and Testing Compounds of the Invention for Biological Utility on page 13). Burkly et al. note that it will be recognized by one skilled in the art, that these screens can be arranged to discover antibodies whose activities are conspicuous in one or more of these assays (see paragraph 095 on page 8) and that one of skill in art may easily determined using well known methods whether a particular blocking agent displays biological activity (see Testing Compounds of the Invention for Biological Utility on page 13).

Wilson et al. teach that CD40 ligand – CD40 interactions are desirable given its broad activity in both T helper cell activation and function as well as the absence of redundancy in its signaling pathway (see entire document, particularly column 6, paragraphs 4-5). In addition, Example 8 describes analyzing the effect of CD40 ligand blockade with antibodies on T cell activation using both in vitro and in vivo assays, including T cell proliferation (see columns 20-22).

While applicant appears to focus on the vivo testing aspects of the teachings of Wilson et al., the combined references, including Wilson et al. of record and the newly added Van den Eertwegh et al and Roy et al. which clearly provide for the importance of CD40 ligand expressing T cells and subsequent effector functions in the context of IL-2, IL-4 and  $\gamma$ -interferon provide clear teachings of the known assays to test inhibitory antibodies, antibodies that inhibit T cell activation and proliferation, including antibodies that inhibit CD40 ligand : CD40 interactions.

Therefore, it would have obvious to a person of ordinary skill in the art at the time the invention was made to apply the teachings of newly added Van den Eertwegh et al and Roy et al. to those of Schrader et al., Burkly et al. and Wilson et al. as well as to those of Black et al. to screen and obtain antagonistic anti-gp39 antibodies with the ability to inhibit cytokines produced by activated T cells, including the inhibition of IL-2, IL-4 and  $\gamma$ -interferon, which were known to be products of the T cells targeted by antagonistic anti-gp39 antibodies.

Art Unit: 1644

According to Black et al., a person of ordinary skill in the art would have been motivated to produce this resultant ability of anti-gp39 antibodies to inhibit cytokine activity by activated T cells in order to test and select for those anti-gp39 antibodies that had the described properties of inhibiting gp39:CD40 interaction and the resultant ability of such antibodies to inhibit T cell mediated activation of immune response in the treatment of various conditions and disorders, including multiple sclerosis.

From the teachings of the references, it was apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

Applicant's arguments have not been found persuasive.

4. No claim allowed.

5. All claims are drawn to the same invention claimed in the application prior to the entry of the submission under 37 CFR 1.114 and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, THIS ACTION IS MADE FINAL even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Art Unit: 1644

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Phillip Gambel whose telephone number is (571) 272-0844. The examiner can normally be reached Monday through Thursday from 7:30 am to 6:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841.

The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Phillip Gambel, Ph.D., J.D.  
Primary Examiner  
Technology Center 1600  
June 20, 2007